Stock IRWD IRONWOOD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
6.54 USD +2.99% Intraday chart for Ironwood Pharmaceuticals, Inc. -3.96% -42.83%
Jun. 10 Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing MT
May. 22 Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
BU
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure
AQ
Ironwood Pharmaceuticals : Late-Breaker Oral Presentation at Digestive Disease Week®
PU
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BU
Ironwood Pharmaceuticals : 1Q 2024 Investor Update
PU
Ironwood: Q1 Earnings Snapshot
AQ
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
BU
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
BU
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
BU
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
BU
Ironwood Pharmaceuticals : ESG/Responsibility
PU
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
BU
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure
AQ
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BU
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science and Practice Conference
AQ
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
BU
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results, Achieves 2023 Financial Guidance
AQ
Ironwood: Q4 Earnings Snapshot
AQ
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
BU
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IRWD Stock
  4. News Ironwood Pharmaceuticals, Inc.
  5. Press Releases